221 related articles for article (PubMed ID: 32215730)
1. The fellow eye effect of unilateral intravitreal conbercept injections in eyes with diabetic macular edema.
Di Y; Li Z; Ye J; Li L; Li B; Yu R
Acta Diabetol; 2020 Aug; 57(8):1001-1007. PubMed ID: 32215730
[TBL] [Abstract][Full Text] [Related]
2. [Treatment response to Conbercept of different types of diabetic macular edema classified based on optical coherence tomography].
Zhang Y; Yao J; Quan Y; Wang J; Xing Y; Zhou A
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1501-1508. PubMed ID: 34755665
[TBL] [Abstract][Full Text] [Related]
3. One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema.
Li F; Zhang L; Wang Y; Xu W; Jiao W; Ma A; Zhao B
Curr Eye Res; 2018 Feb; 43(2):218-223. PubMed ID: 29265939
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.
Xu Y; Rong A; Xu W; Niu Y; Wang Z
BMC Ophthalmol; 2017 Aug; 17(1):158. PubMed ID: 28841827
[TBL] [Abstract][Full Text] [Related]
5. OPTICAL COHERENCE TOMOGRAPHY PREDICTORS OF SHORT-TERM VISUAL ACUITY IN EYES WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL CONBERCEPT.
Tang F; Qin X; Lu J; Song P; Li M; Ma X
Retina; 2020 Apr; 40(4):773-785. PubMed ID: 30640282
[TBL] [Abstract][Full Text] [Related]
6. Hyperreflective foci in OCT image as a biomarker of poor prognosis in diabetic macular edema patients treating with Conbercept in China.
Liu S; Wang D; Chen F; Zhang X
BMC Ophthalmol; 2019 Jul; 19(1):157. PubMed ID: 31337360
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal injection of methotrexate in persistent diabetic macular edema: a 6-month follow-up study.
Falavarjani KG; Golabi S; Modarres M
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2159-2164. PubMed ID: 27145784
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice.
Sato S; Shinoda H; Nagai N; Suzuki M; Uchida A; Kurihara T; Kamoshita M; Tomita Y; Iyama C; Minami S; Yuki K; Tsubota K; Ozawa Y
Medicine (Baltimore); 2017 Apr; 96(16):e6459. PubMed ID: 28422835
[TBL] [Abstract][Full Text] [Related]
9. One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema.
Zhou Q; Guo C; You A; Wang D; Wang W; Zhang X
Mol Vis; 2019; 25():636-644. PubMed ID: 31700228
[TBL] [Abstract][Full Text] [Related]
10. Prospective Clinical Trial of Intravitreal Aflibercept Treat-and-extend Regimen for Diabetic Macular Edema: 1-Year Outcomes.
Mieno H; Yoneda K; Terao N; Yoshii K; Kojima K; Nagata K; Sotozono C
Korean J Ophthalmol; 2020 Aug; 34(4):290-296. PubMed ID: 32783421
[TBL] [Abstract][Full Text] [Related]
11. Atrophy of the central neuroretina in patients treated for diabetic macular edema.
Karst SG; Schuster M; Mitsch C; Meyer EL; Kundi M; Scholda C; Schmidt-Erfurth UM
Acta Ophthalmol; 2019 Dec; 97(8):e1054-e1061. PubMed ID: 31228332
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
13. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
Bahrami B; Hong T; Schlub TE; Chang AA
Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Efficacy of Intravitreal Conbercept Injections with or without Focal Macular Photocoagulation for Diabetic Macular Edema.
Mao Y; Wang S; Ji X; Cao K; Hou S; Xiao Y
Altern Ther Health Med; 2023 Jul; 29(5):308-313. PubMed ID: 37171942
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
[TBL] [Abstract][Full Text] [Related]
17. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
[TBL] [Abstract][Full Text] [Related]
18. Predictors of visual recovery in patients with macular edema secondary to central retinal vein occlusion after treatment with Conbercept.
Zhang Q; Hou Y; Cao X; Zhang R; Liu Y; Wei C; Wu C; Mei L; Zhang P
BMC Ophthalmol; 2021 Nov; 21(1):402. PubMed ID: 34809591
[TBL] [Abstract][Full Text] [Related]
19. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye.
Bakbak B; Ozturk BT; Gonul S; Yilmaz M; Gedik S
J Ocul Pharmacol Ther; 2013 Oct; 29(8):728-32. PubMed ID: 23848950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
